TransMedics Group, Inc.
TMDXHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeTransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. At a $2.44B market cap, TransMedics Group, Inc. ranks as a mid-cap company within healthcare. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Market Cap
$2.44B
Beta
1.93
P/E (TTM)
18.33
P/E (Fwd)
31.38
EPS (TTM)
$3.86
EPS (Fwd)
$2.25
ROE
36.3%
ROA
4.3%
Cash
$472.7M
Total Debt
$867.7M
Free CF
$44.5M
52W Change
-46.6%
Annual Financials
Cash vs Debt
Where TMDX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TMDX finished 15.50% below its 150-day moving average ($84.73) and 26.48% below its 200-day moving average ($97.39). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TMDX overbought or oversold?
At the October 20, 2026 close, TMDX's RSI(14) was 28.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, TMDX has $472.7M in cash with $867.7M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $44.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 36.3% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.3% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $93.5M (2022) to $605.5M (2025), reflecting a 548% increase over the period.
A beta of 1.93 means TMDX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TMDX.